Polyrizon signs non-binding LOI to expand its intranasal drug delivery platform

Polyrizon (PLRZ) announced that it has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived therapeutics, to develop a novel intranasal formulation for psychedelic-based treatment applications. This agreement aims to leverage Polyrizon’s proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug delivery in the psychedelic medicine space, offering an innovative approach to enhancing bioavailability, efficacy, and patient accessibility. If successful, this collaboration has the potential to pave the way for further clinical development and commercialization.